Specifically, the GIP-GLP-1 co-agonism allow to reach a better glycemic control and weight reduction in subjects with obesity and diabetes (15, 144), as both these gastrointestinal hormones account for meal-mediated insulin secretion (145), have an insulinotropic action, and act centrally and peripherally to reduce appetite and stimulate satiety. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.